Market Overview:
Scopolamine is an anticholinergic alkaloid which is found in plants of the family Solanaceae, such as Datura stramonium and Atropa belladonna. It is used for preventing nausea, vomiting, and dizziness caused by motion sickness. Scopolamine patches prevents the transmission of nerve impulses responsible for nausea and vomiting, which provides relief to patients suffering from motion sickness.

Market key trends:
One of the key trend in the Scopolamine market is the rising adoption of transdermal patches. Transdermal patches provide a convenient way of continuous administration of scopolamine through the skin and avoids first-pass effect. Transdermal patches deliver a consistent dose of scopolamine and provide relief for up to 3 days from nausea and vomiting associated with motion sickness. Transdermal scopolamine patches have demonstrated increased patient compliance as compared to oral dosage forms. Rising sea and air travel has fueled the demand for motion sickness treatments using scopolamine patches.

Segment Analysis
The scopolamine market is segmented into scopolamine patch, scopolamine injection, and others. Among these, the scopolamine patch segment holds the largest market share due to the higher convenience and ease of use associated with scopolamine patches for the treatment of motion sickness. Scopolamine patches provide extended relief from nausea and vomiting caused by motion sickness as the drug is delivered continuously through the skin.

The global Scopolamine Market Share is estimated to be valued at US$ 3676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Key Takeaways
The global scopolamine market is expected to witness high growth, exhibiting a CAGR of 4.8% over the forecast period, due to increasing prevalence of motion sickness worldwide.

North America is expected to dominate the global scopolamine market over the forecast period owing to high awareness regarding motion sickness and increasing preference for non-invasive drug delivery methods.

Key players operating in the scopolamine market are Baxter International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company plc, Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation. Key players are focused on developing innovative drug delivery formulations to expand their market share.

Read more: https://www.dailyprbulletin.com/pharmaceutical-industry-to-boost-the-growth-size-and-share-analysis/